Neratinib for the treatment of breast cancer

References

• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.
   PubMed Web of Science ®Google Scholar
• Puglisi F, Fontanella C, Amoroso V, et al. Current challenges in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2016;98:211–221.
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Ross JS, Wang K, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The Oncologist. 2015;20:7–12.
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878–5887.
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603–617.
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science. 2002;297:63–64.
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–237.
   PubMed Web of Science ®Google Scholar
• Martin M, López-Tarruella S. Emerging therapeutic options for HER2-positive breast cancer. Am Soc Clin Oncol Educ Book. 2016;35:e64–e70.
   Google Scholar
• Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005;48:1107–1131.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64:3958–3965.
   PubMed Web of Science ®Google Scholar
• Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer. 2015;7:147–162.
   PubMed Web of Science ®Google Scholar
• Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15:2552–2558.
   PubMed Web of Science ®Google Scholar
• Hug B, Abbas R, Leister C, et al. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res. 2010;16:4016–4023.
   PubMed Web of Science ®Google Scholar
• Abbas R, Hug BA, Leister C, et al. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Brit J Pharmacol. 2011;71:522–527.
   Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301–1307.
   PubMed Web of Science ®Google Scholar
• Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49:3763–3772.
   PubMed Web of Science ®Google Scholar
• Awada A, Dirix L, Manso Sanchez L, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24:109–116.
   PubMed Web of Science ®Google Scholar
• Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013;108:1985–1993.
   PubMed Web of Science ®Google Scholar
• Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32:3626–3633.
   PubMed Web of Science ®Google Scholar
• Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer. The NEfERT-T randomized clinical trial. JAMA Onc. 2016. doi:10.1001/jamaoncol.2016.0237.
   PubMedGoogle Scholar
• Pegram MD. Neratinib in ERBB2-positive brain metastases. JAMA Onc. 2016. DOI:10.1001/jamaoncol.2016.0238.
   PubMedGoogle Scholar
• Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol. 2009;27(15s), (suppl; abstr 1004). Available from: http://meetinglibrary.asco.org/content/34411–65.
   Google Scholar
• Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP foundation research program phase I study. Cancer Chemother Pharmacxol. 2013;72:1205–1212.
   PubMed Web of Science ®Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Robidoux A, Garcia JMP, et al. NSABP FB-7: a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. In: Presented at: San Antonio Breast Cancer Symposium; 2015. San Antonio, TX. Abstract PD5-04.
   Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-contyrolled phase 3 trial. Lancet Oncol. 2016;17:367–377.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. Two years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382:1021–1028.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Sheehan CE, et al. Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013;19:2668–2676.
   PubMed Web of Science ®Google Scholar
• Bose R, Neu A. View of invasive lobular breast cancer. Clin Cancer Res. 2013;19:3331–3333.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Zabransky DJ, Yankaskas CL, Cochran RL, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015;112:E6205–E6214.
   PubMed Web of Science ®Google Scholar
• Ben-Baruch NE1, Bose R2, Kavuri SM3, et al. HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor. J Natl Compr Canc Netw. 2015;13:1061–1064.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Rodón J. Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial abstract. In: San Antonio Breast Cancer Symposium; 2015 December 8–12; San Antonio, TX.
   Google Scholar
• Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–2977.
   PubMed Web of Science ®Google Scholar
• Aversa C, Rossi V, Geuna E, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23:623–628.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452–1459.
   PubMed Web of Science ®Google Scholar
• Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2 – positive metastatic breast cancer. J Clin Onc. 2015;33(14):1564–1573.
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Wefel JS, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Onc. 2016;34:945–952.
   PubMed Web of Science ®Google Scholar